WO2004112706A3 - Vaccines, immunotherapeutics and methods for using the same - Google Patents

Vaccines, immunotherapeutics and methods for using the same Download PDF

Info

Publication number
WO2004112706A3
WO2004112706A3 PCT/US2004/019028 US2004019028W WO2004112706A3 WO 2004112706 A3 WO2004112706 A3 WO 2004112706A3 US 2004019028 W US2004019028 W US 2004019028W WO 2004112706 A3 WO2004112706 A3 WO 2004112706A3
Authority
WO
WIPO (PCT)
Prior art keywords
trail
immunogen
sap
methods
compositions
Prior art date
Application number
PCT/US2004/019028
Other languages
French (fr)
Other versions
WO2004112706A2 (en
Inventor
David B Weiner
Karuppiah Muthumani
Michele Kutzler
Andrew K Choo
Michael A Chattergoon
Original Assignee
Univ Pennsylvania
David B Weiner
Karuppiah Muthumani
Michele Kutzler
Andrew K Choo
Michael A Chattergoon
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Pennsylvania, David B Weiner, Karuppiah Muthumani, Michele Kutzler, Andrew K Choo, Michael A Chattergoon filed Critical Univ Pennsylvania
Priority to EP04755303A priority Critical patent/EP1633372B1/en
Priority to AT04755303T priority patent/ATE535249T1/en
Priority to AU2004249191A priority patent/AU2004249191B2/en
Priority to US10/560,653 priority patent/US8008265B2/en
Priority to CA002529051A priority patent/CA2529051A1/en
Priority to JP2006533794A priority patent/JP2007502868A/en
Publication of WO2004112706A2 publication Critical patent/WO2004112706A2/en
Publication of WO2004112706A3 publication Critical patent/WO2004112706A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/21—Retroviridae, e.g. equine infectious anemia virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2740/00—Reverse transcribing RNA viruses
    • C12N2740/00011—Details
    • C12N2740/10011—Retroviridae
    • C12N2740/16011—Human Immunodeficiency Virus, HIV
    • C12N2740/16111—Human Immunodeficiency Virus, HIV concerning HIV env
    • C12N2740/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Communicable Diseases (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)

Abstract

Compositions, recombinant vaccines and live attenuated pathogens comprising one or more isolated nucleic acid molecules that encode an immunogen in combination with an isolated nucleic acid molecule that encodes an immunomodulator protein selected from the group consisting of: Fos, c-jun, Sp-1, Ap-1, Ap-2, p38, p65Rel, MyD88, IRAK, TRAF6, IkB, Inactive NIK, SAP K, SAP-1, JNK, interferon response genes, NFkB, Bax, TRAIL, TRAILrec, TRAILrecDRC5, TRAIL-R3, TRAIL-R4, RANK, RANK LIGAND, Ox40, Ox40 LIGAND, NKG2D, MICA, MICB, NKG2A, NKG2B, NKG2C, NKG2E, NKG2F, TAPI, TAP2 and functional fragments thereof are disclosed. Methods of inducing an immune response in an individual against an immunogen, using such compositions are disclosed.
PCT/US2004/019028 2003-06-13 2004-06-14 Vaccines, immunotherapeutics and methods for using the same WO2004112706A2 (en)

Priority Applications (6)

Application Number Priority Date Filing Date Title
EP04755303A EP1633372B1 (en) 2003-06-13 2004-06-14 Vaccines, immunotherapeutics and methods for using the same
AT04755303T ATE535249T1 (en) 2003-06-13 2004-06-14 VACCINES, IMMUNOTHERAPEUTICS AND METHODS FOR USE THEREOF
AU2004249191A AU2004249191B2 (en) 2003-06-13 2004-06-14 Vaccines, immunotherapeutics and methods for using the same
US10/560,653 US8008265B2 (en) 2003-06-13 2004-06-14 Vaccines, immunotherapeutics and methods for using the same
CA002529051A CA2529051A1 (en) 2003-06-13 2004-06-14 Vaccines, immunotherapeutics and methods for using the same
JP2006533794A JP2007502868A (en) 2003-06-13 2004-06-14 Vaccines, immunotherapeutic agents and methods of use

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US47825003P 2003-06-13 2003-06-13
US47818703P 2003-06-13 2003-06-13
US60/478,250 2003-06-13
US60/478,230 2003-06-13
US60/478,187 2003-06-13
US47823004P 2004-06-13 2004-06-13

Publications (2)

Publication Number Publication Date
WO2004112706A2 WO2004112706A2 (en) 2004-12-29
WO2004112706A3 true WO2004112706A3 (en) 2005-04-14

Family

ID=44886306

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/019028 WO2004112706A2 (en) 2003-06-13 2004-06-14 Vaccines, immunotherapeutics and methods for using the same

Country Status (7)

Country Link
US (1) US8008265B2 (en)
EP (1) EP1633372B1 (en)
JP (1) JP2007502868A (en)
AT (1) ATE535249T1 (en)
AU (1) AU2004249191B2 (en)
CA (1) CA2529051A1 (en)
WO (1) WO2004112706A2 (en)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007023725A1 (en) * 2005-08-25 2007-03-01 Yokohama City University Gene vaccine
AU2006351377A1 (en) * 2006-11-30 2008-06-05 University Of British Columbia Poxviridae treatment comprising TAP-1 and/or TAP-2 as a molecular adjuvant
GB0719509D0 (en) * 2007-10-05 2007-11-14 Isis Innovation Molecular adjuvant
AU2009231598B2 (en) * 2008-04-04 2015-03-12 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics using IL-28 and compositions and methods of using the same
WO2009124312A2 (en) * 2008-04-04 2009-10-08 The Trustees Of The University Of Pennsylvania Consensus sequences of chikungunya viral proteins, nucleic acid molecules encoding the same, and compositions and methods for using the same
US8685939B2 (en) * 2008-11-06 2014-04-01 Wayne State University Vaccine targeting cellular death receptor DR5
WO2010120271A1 (en) * 2009-04-13 2010-10-21 Cyto Pulse Sciences, Inc. Use of vectors expressing intracellular polynucleotide binding proteins as adjuvants
WO2011032179A1 (en) 2009-09-14 2011-03-17 The Trustees Of The University Of Pennsylvania Vaccines and immunotherapeutics comprising il-15 receptor alpha and/or nucleic acid molecules encoding the same, and methods for using the same
WO2014145038A1 (en) 2013-03-15 2014-09-18 The Trustees Of The University Of Pennsylvania Vaccines with biomolecular adjuvants
CA2987410A1 (en) 2015-05-29 2016-12-08 Bristol-Myers Squibb Company Antibodies against ox40 and uses thereof
CN111494616A (en) * 2020-04-27 2020-08-07 重庆医科大学附属永川医院 New coronavirus immune enhanced gene vaccine and preparation method thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044129A1 (en) * 1997-03-27 1998-10-08 The Council Of The Queensland Institute Of Medical Research Enhancement of immune response using targeting molecules

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077044A (en) 1980-05-19 1991-12-31 The Board Of Trustees Of The Leland Stanford Jr. University Novel non-reverting shigella live vaccines
US5338683A (en) 1981-12-24 1994-08-16 Health Research Incorporated Vaccinia virus containing DNA sequences encoding herpesvirus glycoproteins
US4722848A (en) 1982-12-08 1988-02-02 Health Research, Incorporated Method for immunizing animals with synthetically modified vaccinia virus
US5110587A (en) 1981-12-24 1992-05-05 Health Research, Incorporated Immunogenic composition comprising synthetically modified vaccinia virus
US5174993A (en) 1981-12-24 1992-12-29 Health Research Inc. Recombinant avipox virus and immunological use thereof
US4945050A (en) 1984-11-13 1990-07-31 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
US5036006A (en) 1984-11-13 1991-07-30 Cornell Research Foundation, Inc. Method for transporting substances into living cells and tissues and apparatus therefor
GB8508845D0 (en) 1985-04-04 1985-05-09 Hoffmann La Roche Vaccinia dna
US5223424A (en) 1985-09-06 1993-06-29 Prutech Research And Development Attenuated herpesviruses and herpesviruses which include foreign DNA encoding an amino acid sequence
US5310668A (en) 1986-06-20 1994-05-10 Merck & Co., Inc. Varicella-zoster virus as a live recombinant vaccine
US5242829A (en) 1986-09-23 1993-09-07 Therion Biologics Corporation Recombinant pseudorabies virus
US5387744A (en) 1987-06-04 1995-02-07 Washington University Avirulent microbes and uses therefor: Salmonella typhi
IL86583A0 (en) 1987-06-04 1988-11-15 Molecular Eng Ass Vaccine containing a derivative of a microbe and method for the production thereof
US5294441A (en) 1987-06-04 1994-03-15 Washington University Avirulent microbes and uses therefor: salmonella typhi
US5112749A (en) 1987-10-02 1992-05-12 Praxis Biologics, Inc. Vaccines for the malaria circumsporozoite protein
ATE151467T1 (en) 1987-11-30 1997-04-15 Univ Iowa Res Found DNA MOLECULES STABILIZED BY MODIFICATIONS TO THE 3'-TERMINAL PHOSPHODIESTER BOND, THEIR USE AS NUCLEIC ACID PROBE AND AS THERAPEUTIC AGENTS FOR INHIBITING THE EXPRESSION OF SPECIFIC TARGET GENES
JP3044062B2 (en) 1989-03-08 2000-05-22 ヘルス・リサーチ・インク Recombinant poxvirus host selection system
US5225336A (en) 1989-03-08 1993-07-06 Health Research Incorporated Recombinant poxvirus host range selection system
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
DK0465560T3 (en) 1989-03-31 1996-10-28 Univ Washington Vaccines containing avirulent phoP-type microorganisms
ES2070997T3 (en) 1989-12-04 1995-06-16 Akzo Nobel Nv RECOMBINANT HERPES VIRUSES OF TURKEYS AND LIVING VECTOR VACCINES DERIVED FROM THEM.
US5294548A (en) 1990-04-02 1994-03-15 American Biogenetic Sciences, Inc Recombianant Hepatitis a virus
US5462734A (en) 1990-11-02 1995-10-31 Wisconsin Alumni Research Foundation Bovine herpesvirus vaccine and method of using same
US5240703A (en) 1991-03-01 1993-08-31 Syntro Corporation Attenuated, genetically-engineered pseudorabies virus s-prv-155 and uses thereof
US5593972A (en) 1993-01-26 1997-01-14 The Wistar Institute Genetic immunization
US5981505A (en) 1993-01-26 1999-11-09 The Trustees Of The University Of Pennsylvania Compositions and methods for delivery of genetic material
DK0681483T3 (en) 1993-01-26 2005-11-21 Univ Pennsylvania Preparations and methods for administering genetic material
WO1994020116A1 (en) 1993-03-10 1994-09-15 University Of Alabama Research Foundation Artificial primers for glycogen synthesis
US5739118A (en) 1994-04-01 1998-04-14 Apollon, Inc. Compositions and methods for delivery of genetic material
NL9401820A (en) 1994-11-02 1996-06-03 Meyn Maschf Device for processing poultry suspended from its legs.
US5962428A (en) 1995-03-30 1999-10-05 Apollon, Inc. Compositions and methods for delivery of genetic material
US6344445B1 (en) * 1995-10-19 2002-02-05 Cantab Pharmaceutical Research Limited Herpes virus vectors and their uses
US6017735A (en) * 1997-01-23 2000-01-25 Marie Curie Cancer Care Materials and methods for intracellular transport and their uses
CA2321161C (en) 1998-02-24 2011-12-20 Andrew D. Weinberg Compositions containing an ox-40 receptor binding agent or a nucleic acid encoding the same and methods for enhancing antigen-specific immune response
US20030064072A9 (en) * 1999-03-12 2003-04-03 Rosen Craig A. Nucleic acids, proteins and antibodies
AU2002320079A1 (en) 2001-06-11 2002-12-23 Jeong-Im Sin Vaccines, immunotherapeutics and methods of using the same
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998044129A1 (en) * 1997-03-27 1998-10-08 The Council Of The Queensland Institute Of Medical Research Enhancement of immune response using targeting molecules

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
CLEMENT A. ET AL.: "Prime-boost immunization with DNA and modified vaccinia virus Ankara vector expressing herepes simplex virus-2 glycoprotein D elicits greater specific antibody and cytokine responses than DNA veccine alone", THE J. OF INFECTIOUS DISEASES, vol. 186, 2002, pages 1065 - 1073, XP002982834 *
LUO Y. ET AL.: "Transcription factor Fos-related antigen 1 is an effective target for a breast cancer vaccine", PNAS, vol. 100, no. 15, July 2003 (2003-07-01), pages 8850 - 8855, XP002982835 *
MURAKAMI M.: "HIgh-level expression of exogenous genes by replication-competent retrovirus vectors with an internal ribosomal entry site", GENE, vol. 202, November 1997 (1997-11-01), pages 23 - 29, XP000749204 *

Also Published As

Publication number Publication date
AU2004249191A1 (en) 2004-12-29
CA2529051A1 (en) 2004-12-29
WO2004112706A2 (en) 2004-12-29
US8008265B2 (en) 2011-08-30
EP1633372A4 (en) 2007-07-18
EP1633372A2 (en) 2006-03-15
JP2007502868A (en) 2007-02-15
EP1633372B1 (en) 2011-11-30
ATE535249T1 (en) 2011-12-15
US20070104686A1 (en) 2007-05-10
AU2004249191B2 (en) 2011-01-06

Similar Documents

Publication Publication Date Title
WO2004112706A3 (en) Vaccines, immunotherapeutics and methods for using the same
WO2015095249A8 (en) Single chain il-12 nucleic acids, polypeptids, and uses thereof
EP3424524A3 (en) Cancer rna-vaccine
JP2017122120A5 (en)
DK2135878T3 (en) Tumor-associated peptides promiscuously binding to human leukocyte antigen (HLA) class II molecules
WO2018189152A3 (en) Peptides and combination of peptides for use in immunotherapy against leukemias and other cancers
WO2017001491A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
WO2017005733A3 (en) Novel peptides and combination of peptides for use in immunotherapy against esophageal cancer and other cancers
EA202191027A3 (en) NEW PEPTIDES AND COMBINATIONS OF PEPTIDES FOR USE IN IMMUNOTHERAPY OF SEVERAL TYPES OF TUMORS
TW200507874A (en) Immunostimulatory nucleic acid oil-in-water formulations and related methods of use
EP2184360A3 (en) Novel bacillus thuringiensis crystal polypeptides, polynucleotides, and compositions thereof
EP4035675A3 (en) Novel peptides and combination of peptides for use in immunotherapy against ovarian cancer and other cancers
EP3266798A3 (en) Improved tnf binders
WO2007050095A3 (en) Improved vaccines and methods for using the same
WO2018042385A3 (en) Methods and compositions involving interleukin-6 receptor alpha-binding single chain variable fragments
WO2004083404A3 (en) Gene therapy vectors having reduced immunogenicity based on cd8 alpha-chain
EP2135876A3 (en) Compositions of polypeptides specific to pathogenic strains and their use as vaccines and in immunotherapy
DK1569696T3 (en) Methods and Immunomodulatory Nucleic Acid Preparations for the Prevention and Treatment of Diseases
WO2009124309A3 (en) Vaccines and immunotherapeutics using il-28 and compositions and methods of using the same
EP4272822A3 (en) Adamts binding immunoglobulins
WO2005049647A3 (en) Compositions comprising melittin-derved peptides and methods for the potentiation of immune responses against target antigens
WO2020127546A3 (en) Immunotherapy with b*08 restricted peptides and combination of peptides against cancers and related methods
BRPI0604365A (en) isolated polypeptide, multi-tick vaccine composition, and use thereof
WO2006110881A3 (en) Yersinia polypeptide vaccines, antibodies and immunomodulatory proteins
DE60325477D1 (en) BIRD CYTOKINS, SUCH AS IL-12, CONSISTING OF A P40 AND / OR P35 SUB-UNIT (S)

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref document number: 2529051

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2004249191

Country of ref document: AU

Ref document number: 2006533794

Country of ref document: JP

WWE Wipo information: entry into national phase

Ref document number: 2004755303

Country of ref document: EP

ENP Entry into the national phase

Ref document number: 2004249191

Country of ref document: AU

Date of ref document: 20040614

Kind code of ref document: A

WWP Wipo information: published in national office

Ref document number: 2004249191

Country of ref document: AU

WWP Wipo information: published in national office

Ref document number: 2004755303

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007104686

Country of ref document: US

Ref document number: 10560653

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 10560653

Country of ref document: US